TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02542605

Intervention type: DRUG
Group type: OTHER
Intervention: PACAP-38 Challenge Agent
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PACAP-38 Challenge Agent
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Study: NCT04239820

Intervention type: RADIATION
Intervention: Imaging
Description: MRI and TSPO-PET imaging at baseline and 18 months after baseline
Study: NCT04135326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05568082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral capsule
Study: NCT04135326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Undergo tDCS
Study: NCT02730026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen and Omeprazole
Description: Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
Study: NCT04420078

Intervention type: PROCEDURE
Intervention: Catheter Ablation
Description: Ventricular fibrillation substrate
Study: NCT01741363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) Two-day sampling
Description: Collect two stool samples in two separate days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) Two-day sampling
Description: Collect two stool samples in two separate days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) One-year interval
Description: Screening with one-year interval
Study: NCT04115748

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Injection administered subcutaneously once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Injection administered subcutaneously once every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match adalimumab
Description: Injection administered subcutaneously once every 2 weeks
Study: NCT00654745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg tablets , Daily for 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine / olmesartan medoxomil combination
Description: amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: hydrochlorothiazide tablets, 12.5 mg or 25 mg.
Study: NCT01390831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® Catheter
Description: Catheter-based renal denervation
Study: NCT04685720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungFit
Description: LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
Study: NCT04176991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01741363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) One-year interval
Description: Screening with one-year interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT(Eiken OC-Sensor) One-day sampling
Description: One-day sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) One-day sampling
Description: One-day sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) One-day sampling
Description: One-day sampling
Study: NCT03291054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
Study: NCT00648427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
Description: 25mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR™ Tablets 25 mg
Description: 25mg, single dose fasting
Study: NCT04043455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
Study: NCT02079740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo conventional CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT01741363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT(Eiken OC-Sensor) One-day sampling
Description: One-day sampling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT(Eiken OC-Sensor) Two-year interval
Description: Screening with two-year interval
Study: NCT01591837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Influenza Vaccine
Description: The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Influenza Vaccine
Description: The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
Study: NCT03723551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afabicin
Description: Administered intravenously and orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Administered with SOC in accordance with local practice and applicable treatment guidelines.
Study: NCT05066503

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 260279 active study product
Description: The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.
Study: NCT02807129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood withdrawn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine collection
Study: NCT03422822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
Study: NCT04477200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 40.5 Gy in 15 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-resection (as part of standard of care)
Description: Re-resection or biopsy of tumor as part of standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 250-2000mg orally twice daily, one week prior to and concurrent with RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 60 Gy in 30 fractions
Study: NCT03711214

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal scaling
Description: Periodontal scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal scaling
Description: Periodontal scaling and root planing
Study: NCT00985608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A: NCA 600 mg+antibiotics
Description: NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B: antibiotic treatment (control)
Description: patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
Study: NCT03470194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Modality: In Person
Description: Use of In-Person interpretation support for LEP participant during clinical appointment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Modality: Telephonic
Description: Use of telephonic interpretation support for LEP participant during clinical appointment
Study: NCT02963363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Adapted Physical Activity
Description: Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks
Study: NCT03090659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-B38M CAR-T cell injection
Study: NCT01038479

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol consumption
Description: Mothers will eat 6 grams of xylitol per day

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Childsmile preventative programme
Description: Mothers will receive the childsmile preventative programme

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Childsmile preventative programme
Description: Mothers will receive the childsmile preventative programme
Study: NCT01764269

Intervention type: OTHER
Group type: OTHER
Intervention: text message surveillance for fever

Intervention type: OTHER
Group type: OTHER
Intervention: text message surveillance for fever
Study: NCT03694340

Intervention type: OTHER
Group type: OTHER
Intervention: Re-programming of cochlear implant
Description: New MAP based on behavioral T- and C-levels
Study: NCT01109121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination 400
Description: Tranilast 300 mg QD; Allopurinol 400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 400 mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination 600
Description: Tranilast, 300 mg QD; Allopurinol 600 mg QD
Study: NCT01157572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
Study: NCT00104416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine (LAMICTAL) extended-release
Description: Primary experimental dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT02250794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and sitagliptin
Description: metformin 750 mg PO twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine and insulin lispro
Description: insulin glargine given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and sitagliptin
Description: sitagliptin 100 mg PO once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine and insulin lispro
Description: insulin lispro given three times daily with meals
Study: NCT03322046

Intervention type: BEHAVIORAL
Intervention: Lifestyle Program
Description: 4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
Study: NCT05336929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roy adaptation model-based nursing education
Study: NCT01295840

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: Cardiac Resynchronization Therapy Defibrillator
Study: NCT04400019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Only Product in Oral Dose Form
Description: The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
Study: NCT03271762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW
Description: percutaneous mitral valve repair Percutaneous MitraClip Device Implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac surgery
Description: mitral valve repair or mitral valve remplacement
Study: NCT04016285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamantys
Description: The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
Study: NCT01741363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) Two-year interval
Description: Screening with two-year interval
Study: NCT04016285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: Standard of care for reducing bleeding during the total knee arthroplasty
Study: NCT03716024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 0796
Description: PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
Study: NCT00783003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 and GW642444
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: Inhaled Long acting Beta 2 agonist (LABA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT02931487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: Computerized

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Computerized
Study: NCT00284050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Description: 6 mg/ml ranibizumab solution for intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: 10 mg/ml ranibizumab solution for intravitreal injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Non-treatment control for sham intravitreal injection.
Study: NCT04346602

Intervention type: OTHER
Intervention: all treatment about COVID-2019
Description: All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
Study: NCT04571138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CAR22v2
Description: Single infusion of SCRI-CAR22v2
Study: NCT02093832

Intervention type: OTHER
Intervention: There are no specific Intervention
Description: are no specific Intervention
Study: NCT03763253

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Ablative Therapy (MIAT)
Description: MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Therapy (Prostatectomy or Radiotherapy)
Description: Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use.
Study: NCT01569789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulator
Description: Voltage 2, placed on cymba concha

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vagus Nerve Stimulator
Description: Voltage 2, place on the placebo area of the calf
Study: NCT01170858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin PD solution
Description: 2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose solutions
Study: NCT01502059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates training - twice a week (one hour per class) during 90 days
Study: NCT03258021

Intervention type: DEVICE
Intervention: TTFields
Description: Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.